Program Planning Committee,
Faculty, and CME Committee
Disclosure Information
In accordance with the disclosure policies of the American Society of Addiction
Medicine (ASAM) and the Accreditation Council for Continuing Medical Education
(ACCME), an effort has been made to ensure balance, independence, objectivity, and
scientific rigor in all of ASAM’s educational activities.
These policies include resolving all conflicts of interest involving the CME Committee,
the Program Planning Committee, or the faculty and commercial interests that might
otherwise compromise the educational integrity of this activity.
All CME Committee and Program Planning Committee members and faculty
participating in this activity have disclosed all relevant financial relationships with
commercial interests. The CME Committee has reviewed these disclosures and
determined that the relationships are not inappropriate in the context of the various
presentations and are not inconsistent with the educational goals and integrity of the
activity.
ASAM CME Committee
Adam J. Gordon, M.D., M.P.H., FACP, FASAM, Chair
Edwin A. Salsitz, M.D., FASAM, Co-Chair
Maris Andersons, M.D., FASAM
Jacob Bobrowski, M.D., FAAFP
Anthony H. Dekker, D.O., FASAM
James L. Ferguson, D.O., FASAM
R. Jeffrey Goldsmith, M.D.
Elizabeth Howell, M.D., FASAM
Mark Schwartz, M.D., FASAM, FAAFP
John C. Tanner, D.O., FASAM
CME Committee Reviewers
Mars Andersons, M.D., FASAM
Jacob Bobrowski, M.D., FAAFP
Mark Schwartz, M.D., FASAM, FAAFP
ASAM Disclosure of Relevant Financial Relationships
Content of Activity: ASAM 2011 Course on the State of the Art in Addiction Medicine,
Date of Activity:
October 27-29, 2011 - Washington, DC
ASAM CME Committee
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Per diem
Dept. of Transportation,
Govt. of Canada
Per diem
College of Physicians &
Surgeons of Ontario
Maris Anderson, M.D.
Jacob Bobrowski, M.D., FAAFP
Nothing to declare
Anthony H. Dekker, D.O.
Nothing to declare
James L. Ferguson, D.O.
Nothing to declare
R. Jeffrey Goldsmith, M.D.
Nothing to declare
Adam J. Gordon, M.D., M.P.H.
Nothing to declare
Elizabeth F. Howell, M.D., FASAM
Nothing to declare
Edwin A. Salsitz, M.D., FASAM
Mark P. Schwartz, M.D.
Honoraria
Advisory panels to
Reckitt-Benckiser,
Pfizer, PriCara, Purdue
Pharma
Nothing to declare
Research funding
Reckitt-Benckiser
Honoraria
Astra Zenica, Alkermes
John C. Tanner, D.O., FASAM
Program Planning Committee
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Anthony Campbell, D.O., R.Ph.
Nothing to declare
H. Westley Clark, M.D., J.D.,
M.P.H., CAS, FASAM
Nothing to declare
Jag H. Khalsa, Ph.D.
Nothing to declare
Margaret Kotz, D.O., FASAM
Honorarium
Raye Z. Litten, Ph.D.
Nothing to declare
Robert Lubran, M.S., M.P.A.
Nothing to declare
Shannon C. Miller, M.D., FASAM
Nothing to declare
Terry A. Rustin, M.D.
Consulting fee
Salary
Salary
Edwin A. Salsitz, M.D., FASAM
Honoraria
Frank J. Vocci, Ph.D.
Consulting fees
Bonnie B. Wilford, M.S.
Nothing to declare
Advisory panel to
Purdue-Pharma
Home Sight
JSA Health
University of Texas
Advisory panels to
Reckitt-Benckiser,
Pfizer, PriCara,
Purdue Pharma
U.S. World Meds,
Dome Rx,
Pinney Associates,
Purdue Pharma,
Reckitt Benckiser, Teva
SESSION 1. Genetics: Shaping
Our Understanding of Addiction
and Its Treatment
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Phil Skolnick, Ph.D., D.Sc. (Hon)
Nothing to declare
David A. Flockhart, M.D., Ph.D.
Nothing to declare
Rita Z. Goldstein, Ph.D.
Nothing to declare
Kent Hutichison, Ph.D.
Honorarium
Purdue Pharma
Consulting fees
DLA Pharma
Adial Pharma
Medico-TANS
Bankole A. Johnson, M.D., Ph.D.,
D.Sc.
Editor's honorarium
Psychological
Education
Publishing
Frontiers in Psychiatry
Raye Z. Litten, Ph.D.
Nothing to declare
Frank J. Vocci, Ph.D.
SESSION 2. Use and Abuse of
Prescription Opioids: Current
Evidence
Linda B. Cottler, Ph.D.
Consulting fees
U.S. World Meds,
Dome Rx,
Pinney Associates,
Purdue Pharma,
Reckitt Benckiser. Teva
Nature of Relevant Financial Relationship
What Was Received
Grant funding
From Whom?
Pinney Associates,
ESPN, JMJ
Technologies,
Terra Nova
SESSION 2. Use and Abuse of
Prescription Opioids: Current
Evidence
Gil R. Kerlikowske
Walter Ling, M.D.
Robert Lubran, M.S., M.P.A.
Edwin A. Salsitz, M.D. FASAM
Lynn R. Webster, M.D.
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Nothing to declare
Research support
Reckitt-Benckiser
Titan Pharmaceuticals
Advisory board
U.S. World Meds.
Alkermes, DemeRx
Nothing to declare
Honoraria
Consultant/Honoraria/
Advisory Board
Advisory panels to
Purdue Pharma,
Reckitt Benckiser,
Pfizer, Pricara
American Board of Pain
Medicine
AstraZeneca
BioDelivery Systems
International
Boston Scientific
Cephalon, Inc.
Covidien Mallinckrodt
Janssen
Pharmaceutical U.K.
King Pharmaceuticals
Naktar Therapeutics
NeurogesX
Nevro Corporation
Pharmacofore, Inc.
Purdue Pharma
Theravance
SESSION 2. Use and Abuse of
Prescription Opioids: Current
Evidence
Nature of Relevant Financial Relationship
What Was Received
Lynn R. Webster, M.D. (contd.)
Research grants
Martha J. Wunsch, M.D., FASAM
Nothing to declare
SESSION 3. Marijuana and the
Cannabinoids
Adolor Corp.
Alkermes, Inc.
Allergan, Inc.
Bayer Healthcare
BioDelivery Systems Int
Boston Scientific
Cephalon
Collegium
Pharmaceuticals
Covidien
Eisai
Elan Pharmaceuticals
Meagan Medical
Medtronic
Nektar Therapeutics
NeurogesX, Inc.
Shionogi USA, Inc.
St. Renatus
SuCampo Pharma
Americas, USA
Teva Pharmaceuticals
(Sub-1)
Theravance, Inc.
Vertex
Xanodyne
Pharmaceuticals
Nature of Relevant Financial Relationship
What Was Received
Salary
Andrea Barthwell, M.D., FASAM
From Whom?
Consulting fee
Board participation
From Whom?
Two Dreams Outer
Banks
GW Pharma
Catasys
SESSION 3. Marijuana and the
Cannabinoids
Robert L. DuPont, M.D.
Eliot Gardner, Ph.D.
Alan Green, M.D.
Terry A. Rustin, M.D., FASAM
SESSION 4. New Therapeutic
Strategies for Co-Occurring
Disorders
Nature of Relevant Financial Relationship
What Was Received
Employment - Salary
Institute for Behavior &
Health, Inc.,
Bensinger Dupont &
Associates
Nothing to declare
Nothing to declare
Nothing to declare
Nature of Relevant Financial Relationship
What Was Received
Chris Beyrer, M.D., M.P.H.
Nothing to declare
Frances M. Harding
Nothing to declare
Jag Khalsa, Ph.D.
Nothing to declare
Howard Koh, M.D., M.P.H.
Nothing to declare
Elinore F. McCance-Katz, M.D.,
Ph.D.
Nothing to declare
Shannon C. Miller, M.D., FAPA,
FASAM
Nothing to declare
Glenn J. Treisman, M.D., Ph.D.
From Whom?
Nothing to declare
From Whom?
SESSION 4. New Therapeutic
Strategies for Co-Occurring
Disorders
Timothy S. Webb, Ph. D.
SESSION 5. Emerging Drugs of
Abuse: A Global Perspective
Nature of Relevant Financial Relationship
What Was Received
Nothing to declare
Nature of Relevant Financial Relationship
What Was Received
Erik Gunderson, M.D.
Nothing to declare
Ralph W. Hingson, Sc.D., M.P.H.
Nothing to declare
Jag Khalsa, Ph.D.
Nothing to declare
Raye Litten, Ph.D.
Nothing to declare
Shannon C. Miller, M.D.
Nothing to declare
Karen Miotto, M.D.
Nothing to declare
SESSION 6. Integrating
Addiction-Related Competencies
Into Physician Training and
Practice
From Whom?
From Whom?
Nature of Relevant Financial Relationship
What Was Received
Daniel P. Alford, M.D., M.P.H.
Nothing to declare
J. Harry Isaacson, M.D.
Nothing to declare
From Whom?
SESSION 6. Integrating
Addiction-Related Competencies
Into Physician Training and
Practice
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Margaret M. Kotz, D.O.
Nothing to declare
David C. Lewis, M.D.
Nothing to declare
Bradley Tanner, M.D.
Salary (President)
Clinical Tools, Inc.
Consulting fees
U.S. World Meds,
Dome Rx
Pinney Associates
Purdue Pharma,
Reckitt Benckiser
* Frank J. Vocci, Ph.D.
SESSION 7. Addiction
Treatment: New Approaches to
Old Problems
H. Westley Clark, M.D., J.D.,
M.P.H., CAS, FASAM
Nature of Relevant Financial Relationship
What Was Received
From Whom?
Nothing to declare
Grant support
Pfizer Medical
Education
Honorarium
GSK Advisory Board
Richard Hurt, M.D., FASAM
Andrew B. Norman, Ph.D.
Nothing to declare
Charles P. O'Brien, M.D., Ph.D.
Nothing to declare
Edwin A. Salsitz, M.D., FASAM
Honoraria
Advisory panels to
Purdue Pharma,
Reckitt Benckiser,
Pfizer, Pricara
SESSION 7. Addiction
Treatment: New Approaches to
Old Problems
Nature of Relevant Financial Relationship
What Was Received
Frank Vocci, Ph.D.
Consulting fees
George E. Woody, M.D.
Nothing to declare
From Whom?
U.S. World Meds,
Dome Rx,
Pinney Associates,
Purdue Pharma,
Reckitt Benckiser
Faculty Roster
Program Planning Committee
Course Chair
H. Westley Clark, M.D., J.D., M.P.H., CAS
Director, Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road, Room 5-1015
Rockville, MD 20857
Committee Members
Anthony Campbell, D.O., R.Ph. (Liaison to CSAT)
CDR., U.S. Public Health Service
Medical Officer, Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
1 Choke Cherry Road, Room 2-1067
Rockville, MD 20857
Jag H. Khalsa, Ph.D. (Liaison to NIDA)
Chief, Medical Consequences Branch
Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC)
National Institute on Drug Abuse
6001 Executive Blvd., Room ____
Bethesda, MD 20892-9561
Margaret Kotz, D.O. (Liaison to AOAAM)
Professor of Psychiatry & Anesthesiology
Case Western Reserve School of Medicine, and
Director of Addiction Services, University Hospitals of Cleveland
10524 Euclid Ave, Ste 3200
Cleveland, OH 44106-2205
Raye Z. Litten, Ph.D. (Liaison to NIAAA)
Associate Director, Division of Treatment and Recovery Research
National Institute on Alcohol Abuse and Alcoholism
10 Center Drive, 10/1-5334
Bethesda, MD 20892
Robert A. Lubran, M.S., M.P.A. (2009 Planning Committee; Liaison to CSAP)
Director, Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
1 Choke Cherry Road, Room 2-1071
Rockville, MD 20857
Shannon C. Miller, M.D., FASAM (Past SOA Course Chair;
Liaison to ASAM Textbook & Journal))
Associate Professor of Clinical Psychiatry, and
Director, Addiction Psychiatry and Addiction Medicine Fellowships
University of Cincinnati College of Medicine
3200 Vine Street, Room B724
Cincinnati, Ohio 45220
Terry A. Rustin, M.D., FASAM (Past SOA Course Chair; Liaison to ASAM Chapters Council)
9731 Greenwillow Street
Houston, TX 77096-4411
Edwin A. Salsitz, M.D., FASAM (Past SOA Course Chair; Liaison to CME Committee)
Medical Director, Office-Based Opioid Therapy
Beth Israel Medical Center
First Ave. at 16th St., Room 10 B 45
New York, NY 10003
Jennifer Shehan (Ex Officio)
Director of Meetings and Conferences
American Society of Addiction Medicine
4601 No. Park Ave., Suite 101 Upper Arcade
Chevy Chase, MD 20815
Frank J. Vocci, Ph.D. (Chair, 2009 SOA Course)
President, Friends Research Institute, Inc.
1040 Park Avenue, Suite 103
Baltimore, MD 21201
Bonnie B. Wilford, M.S. (Course Director)
Executive Director, Coalition on Physician Education
in Substance Use Disorders (COPE)
210 Marlboro Ave., Ste. 31, PMB 287
Easton, MD 21601
Session 1. Genetics: Shaping Our Understanding
of Addiction and Its Treatment
Keynote Speaker
Phil Skolnick, Ph.D., D.Sc. (Hon)
Director, Division of Pharmacotherapies
and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd., Room 4123, MSC 9551
Bethesda, MD 20892-9551
Moderators
Raye Z. Litten, Ph.D.
Associate Director, Division of Treatment and Recovery Research
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, Room 2041
Bethesda, MD 20892
Frank Vocci, Ph.D.
President, Friends Research Institute, Inc.
1040 Park Avenue, Suite 103
Baltimore, MD 21201
Speakers
David A. Flockhart, M.D., Ph.D.
Harry and Edith Gladstein Chair in Cancer Genomics, and
Professor of Medicine, Medical Genetics and Pharmacology, and
Director of the Division of Clinical Pharmacology
Indiana University School of Medicine
Wishard Memorial Hospital
1001 West 10th Street
Indianapolis, Indiana 46202
Rita Z. Goldstein, Ph.D.
Brookhaven National Laboratory
Medical Research Center
Neuropsychoimaging Group, Bldg. 490
P.O. Box 5000
Upton, NY 11973-5000
Kent Hutchison, Ph.D.
Department of Psychiatry and Neuroscience
University of Colorado, Boulder
Muenzinger D325C (345 UCB)
Boulder, CO 80309-0345
Bankole A. Johnson, M.D., Ph.D., D.Sc.
Chair, Department of Psychiatric Medicine
UVA Health Sciences Center
University of Virginia
Box 800623
Charlottesville, VA 22908
Session 2. Use and Abuse of Prescription Opioids: Current Evidence
Keynote Speaker
Gil R. Kerlikowske
Director, Office of National Drug Control Policy
Executive Office of the President
The White House
Washington, DC 20500
Moderators
Robert Lubran, M.S., M.P.A.
Director, Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Rockville, MD 20857
Edwin A. Salsitz, M.D., FASAM
Medical Director, Office-Based Opioid Therapy
Beth Israel Medical Center
First Ave. at 16th St., Room 10 B 45
New York, NY 10003
Speakers
Linda B. Cottler, Ph.D., M.P.H.
Chair and Dean's Professor of Epidemiology
College of Public Health and Health Professions
University of Florida
101 S. Newell Drive, Room 3107
Gainesville, FL 32610
Walter Ling, M.D.
Professor of Psychiatry and
Director, Integrated Substance Abuse Programs
Dept. of Psychiatry & Biobehavioral Sciences
David Geffen School of Medicine at UCLA
11075 Santa Monica Blvd., Suite 200
Los Angeles, California 90025
Lynn R. Webster, M.D., FACPM, FASAM
Medical Director, Lifetree Pain Clinic
3838 South 700 East
Salt Lake City, UT 84106
Session 3. Clinical Challenges in Addiction Medicine: Marijuana
Moderators
Andrea G. Barthwell, M.D., FASAM
Medical Director
Two Dreams Outer Banks, Inc.
815 Lathrop Ave.
River Forest, IL 60305
Terry A. Rustin, M.D.
9731 Greenwillow Street
Houston, TX 77096-4411
Speakers
Andrea G. Barthwell, M.D., FASAM
Medical Director
Two Dreams Outer Banks, Inc.
815 Lathrop Ave.
River Forest, IL 60305
Robert L. DuPont, M.D.
President, Institute for Behavior & Health
6191 Executive Boulevard
Rockville, MD 20852
Eliot L. Gardner, Ph.D.
Neuropsychopharmacology Section
Intramural Research Program
National Institute on Drug Abuse
251 Bayview Blvd., Suite 500, Room 05-A707
Baltimore, MD 21224
Alan I. Green, M.D.
Raymond Sobel Professor of Psychiatry, and
Professor of Pharmacology and Toxicology, and
Director, SYNERGY (Dartmouth Center for Clinical and Translational Science)
Dartmouth Medical School
One Medical Center Drive, HB 7750
Lebanon, NH 03756
Session 4. New Therapeutic Strategies for Co-Occurring Disorders
Keynote Speaker
Frances M. Harding
Director, Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Rockville, MD 20857
Moderators
Jag Khalsa, Ph.D.
Chief, Medical Consequences Branch
Division of Pharmacotherapies
and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd., Room ____
Bethesda, MD 20892-9561
Elinore F. McCance-Katz, M.D., Ph.D.
University of California San Francisco
San Francisco General Hospital
1001 Potrero Ave, Suite 7M-WD93
San Francisco, CA 94410
Speakers
Chis Beyrer, M.D., M.P.H.
Professor and Director
Fogarty AIDS International Training and Research Program
Johns Hopkins University
615 N. Wolfe St., Suite E 7152
Baltimore, MD 21287
Shannon C. Miller, M.D., FASAM, FAPA
Associate Professor of Clinical Psychiatry, and
Director, Addiction Psychiatry and Addiction Medicine Fellowships
University of Cincinnati College of Medicine
3200 Vine Street, Room B724
Cincinnati, Ohio 45220
Glenn J. Treisman, M.D., Ph.D.
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
600 North Wolfe St., Meyer 119
Baltimore, MD 21287-5371
Timothy S. Webb, Ph.D.
Senior Research Statistician
University of Cincinnati College of Medicine
711 Human Performance Wing
(Air Force Research Laboratory)
Cincinnati, Ohio 45220
5ession 5. Emerging Drugs of Abuse: A Global Perspective
Keynote Speaker
Raye Z. Litten, Ph.D.
Associate Director
Division of Treatment and Recovery Research
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, Room 2041
Bethesda, MD 20892
Moderators
Jag H. Khalsa, Ph.D., M.S.
Chief, Medical Consequences Branch
Division of Pharmacotherapies
and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd., Room 4137, MSC 9551
Bethesda, MD 20892-9551
Shannon C. Miller, M.D., FASAM, FAPA
Associate Professor of Clinical Psychiatry, and
Director, Addiction Psychiatry and Addiction Medicine Fellowships
University of Cincinnati College of Medicine
3200 Vine Street, Room B724
Cincinnati, Ohio 45220
Speakers
Erik Gunderson, M.D.
Assistant Professor, Department of Psychiatry
& Neurobehavioral Sciences, and
Department of Medicine, and
Director, Clinical Pharmacological Research Unit
University of Virginia
PO Box 800623
Charlottesville, VA 22908
Ralph W. Hingson, Sc.D., M.P.H.
Director, Division of Epidemiology and Prevention Research
National Institute on Alcohol Abuse & Alcoholism
5635 Fishers Lane, Room 2077
Bethesda, MD 20892-9304
Jag Khalsa, Ph.D.
Chief, Medical Consequences Branch
Division of Pharmacotherapies
and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd., Room ____
Bethesda, MD 20892-9561
Karen Miotto, M.D.
Director of the UCLA Addiction Medicine Service
and Clinical Professor
David Geffen School of Medicine at UCLA
Semel Institute of Neuroscience and Human Behavior
760 Westwood Plaza, Box 175919, Room B8-233A
Los Angeles, CA 90095
Session 6. Integrating Addiction-Related Competencies into
Physician Training and Practice
Moderators
David C. Lewis, M.D.
Professor Emeritus of Community Health and Medicine, and
Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies
Brown University
345 Blackstone Blvd, Potter Building, Room 207
Providence, RI 02906
Margaret Kotz, D.O.
Professor of Psychiatry & Anesthesiology
Case Western Reserve School of Medicine, and
Director of Addiction Services
University Hospitals of Cleveland
10524 Euclid Ave, Ste 3200
Cleveland, OH 44106-2205
Speakers
Daniel P. Alford, M.D., M.P.H., FACP
Associate Professor of Medicine, and
Medical Director, MASBIRT Program
Boston University School of Medicine
801 Massachusetts Avenue, 2nd Floor
Boston, MA 02118
J. Harry (Bud) Isaacson, M.D.
Associate Professor of Medicine and
Director of Clinical Education
Department of General Internal Medicine
The Cleveland Clinic, Lerner College of Medicine
9500 Euclid Avenue, Desk A91
Cleveland, OH 44195
Bradley Tanner, M.D.
President, Clinical Tools, Inc.
1506 E. Franklin Street, Ste. 200
Chapel Hill, NC 27514
Frank Vocci, Ph.D.
President , Friends Research Institute, Inc.
1040 Park Avenue, Suite 103
Baltimore, MD 21201
Session 7. Addiction Treatment: New Approaches to Old Problems
Keynote Speaker
H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM
Director, Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road, Room 5-1015
Rockville, MD 20857
Moderators
Edwin A. Salsitz, M.D., FASAM
Medical Director, Office-Based Opioid Therapy
Beth Israel Medical Center
First Ave. at 16th St., Room 10 B 45
New York, NY 10003
Frank Vocci, Ph.D.
President, Friends Research Institute, Inc.
1040 Park Avenue, Suite 103
Baltimore, MD 21201
Speakers
Richard Hurt, M.D., FASAM
Director, Nicotine Research Center
The Mayo Clinic, Colonial 3
200 - 1st Street, S.W.
Rochester, MN 55905
Andrew T. Norman, Ph.D.
Professor of Psychiatry and
Director of the Division of Neuroscience
University of Cincinnati Academic Health Center
Department of Psychiatry & Behavioral Neuroscience
Genome Research Institute
2170 East Galbraith Road
Cincinnati, OH 45237
Charles P. O'Brien, M.D., Ph.D.
Professor, Department of Psychiatry
The Charles O'Brien Center for Addiction Treatment
University of Pennsylvania School of Medicine
3535 Market Street, 4th Floor
Philadelphia, PA 19104
George E. Woody, M.D.
Professor of Psychiatry
Treatment Research Institute
600 Public Ledger Building
150 South Independence Mall (W)
Philadelphia, PA 19129
ASAM Staff
Penny S. Mills, M.B.A.
Executive Vice President/CEO
American Society of Addiction Medicine
4601 No. Park Ave., Suite 101 Upper Arcade
Chevy Chase, MD 20815
Sandy Metcalfe
CME Consultant
American Society of Addiction Medicine
4601 No. Park Ave., Suite 101 Upper Arcade
Chevy Chase, MD 20815
Jennifer Shehan
Director of Meetings and Conferences
American Society of Addiction Medicine
4601 No. Park Ave., Suite 101 Upper Arcade
Chevy Chase, MD 20815